While a plethora of systematic reviews have provided evidence of efficacy, effectiveness and safety of direct-acting oral anticoagulants (DOACs) in the management of nonvalvular atrial fibrillation, there has been little emphasis on clinicians' perspectives. This systematic review aimed to critically appraise, synthesize and present the available evidence of clinicians' views and experiences.
Introduction
Recent years have seen marked changes in the availability and prescription of oral anticoagulants worldwide. The introduction of dabigatran into the UK market in 2008 was followed by rivaroxaban, apixaban and, most recently, edoxaban. While initially termed new or novel oral anticoagulants, the International Society of Thrombosis and Haemostasis has suggested that direct-acting oral anticoagulant (DOAC) be adopted universally [1] . This is more consistent with the pharmacotherapeutic classifications of direct thrombin inhibitors (dabigatran) or directed Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) [2] .
DOACs have now been incorporated into local, national and international prescribing guidance and policy statements. For example, the National institute for Health and Care Excellence, which provides national guidance and advice to improve health and social care in England and Wales, recommends use of all four DOACs as alternatives to warfarin in nonvalvular atrial fibrillation [3] . DOACs are also recommended within atrial fibrillation management guidelines from the European Society of Cardiology [4] , the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [5] , and the recently updated 2018 Practical Guide from the European Heart Rhythm Association [6] , all of which have retained the term non-vitamin K antagonist oral anticoagulants.
A pharmacoepidemiological study of DOAC prescribing in primary care in the UK from 2009 to 2015 highlighted substantial increases in prescribing over the study period. By 2015, DOACs had surpassed warfarin as the oral anticoagulants of choice, particularly for the management of atrial fibrillation (AF) [7] . While there is an extensive evidence base of systematic reviews and meta-analyses demonstrating effectiveness and safety of DOACs for a range of indications and patient groups, to date no systematic reviews have been published on clinicians' preferences, values or experiences with DOACs. Given current prescribing levels and the expected trend towards increasing use and now being recommended first line for several indications [3] [4] [5] [6] [7] , there is a need for pooled data on their perspectives. The aim of this systematic review was to critically appraise, synthesize and present the available evidence of clinicians' views and experiences of the use of DOACs for the management of nonvalvular AF.
Methods
A systematic review protocol was developed according to the standards of PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) [8] , and subsequently registered with PROSPERO (International Prospective Register of Systematic Reviews) at the University of York, UK [9] .
Inclusion and exclusion criteria
Studies were included if they reported the views and/or experiences of either doctors, nurses or pharmacists on any individual DOAC or as a pharmacological group. All primary research studies of any design (quantitative, qualitative or mixed), published in English from January 2006 (launch of DOACs) to July 2017 were included. Conference abstracts and proceedings were excluded due to the lack of detail for quality assessment and data extraction.
Search strategy
The following databases were searched: Cumulative Index to Nursing & Allied Health Literature (CINAHL), International Pharmaceutical Abstracts, Medline and PsycARTICLES. Search terms (title, abstract, text, keyword) were: (clinician* OR doctor* OR surgeon* OR general practitioner* OR family doctor* OR physician* OR pharmacist* OR nurse* OR health professional* OR healthcare professional* OR health carer* OR practitioner* OR prescriber* OR healthcare provider*) AND (new oral anticoagulant* OR novel oral anticoagulant* OR direct oral anticoagulant* OR nonvitamin K oral anticoagulant* OR dabigatran OR rivaroxaban* OR apixaban OR edoxaban) AND (experience* OR use* OR utility* OR evaluation* OR audit* OR behav* OR knowledge OR satisfaction OR skill* OR practice* OR practise* OR belief* OR attitude* OR view* OR opinion* OR perspective*). The reference lists of all identified papers were reviewed to identify additional studies. A random sample of 10% of titles, abstracts and full papers were screened by an independent researcher to confirm reliability of the screening process.
Quality assessment, data extraction and synthesis
All studies were assessed for quality assessment by two independent reviewers and a third consulted if any disagreements. For quantitative, observational studies an adapted STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist was used [10] , with an adapted COREQ (Consolidated Criteria for Reporting Qualitative Research) checklist for qualitative studies [11] . A piloted tool was used by two independent researchers to extract data of: study aim; country; setting, study design; participants; use of any theory in data collection and analysis; number of participants; and key findings. Given the differences in data collected, quantitative findings were synthesized using a narrative approach. It had been intended that qualitative research would be pooled with aggregation or synthesis of findings to generate a set of statements that represented that aggregation; however, only one qualitative study was identified.
Results

Searching
The PRISMA flowchart is given in Figure 1 . Removal of duplicates and screening of the titles reduced the number of papers from 979 to 394. Screening of the abstracts reduced this number to 195 and a further 186 removed following screening of the full papers. Reasons for exclusion of full papers included: review articles (systematic and narrative, n = 41); editorials and opinion papers (n = 36); no data relating to DOACs (n = 36); clinician reports of patient registries or databases (n = 38); and primary research data on patients' views and experiences only (n = 35). Nine papers were retained for quality assessment plus one further paper identified from screening the reference lists of the nine papers. Of the 10 papers, nine were quantitative (cross-sectional survey-based methodology) and one qualitative (semistructured interview method, no methodology stated).
Quality assessment
Quality assessment is given in Tables 1 and 2 for the quantitative studies and the one qualitative study respectively. For the quantitative studies, key areas of strength were the clarity of statement of study aims and description of participants, settings and outcome measures. Fewer studies provided detailed information on sampling strategies, and justification of sample size was only provided in two studies [12, 15] . There was also a lack of detail provided on the approaches to recruitment. Similarly, very few described any approach to questionnaire development, item selection and pretesting. Notably theory was not used to support development of questionnaire domains and items in any of the studies reviewed.
While the one qualitative study involved semistructured interviews, the study methodology (e.g. phenomenology, grounded theory) was not stated. Key areas of strength were aspects of research trustworthiness (e.g. double coding of interview transcripts and representing the participants' voices through illustrative quotes). Areas of weakness were: the lack of consideration of the researcher perspective, no theory to underpin the development of the interview schedule or coding 
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Study selection process (PRISMA flow diagram) Table 1 Quality assessment of the nine cross-sectional studies using adapted STROBE criteria
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Sauter et al. Clinicians' views, experiences of DOACs framework, and the limited sample size of seven which reduced the potential of obtaining data saturation. All studies were, however, considered to be of sufficient quality to be included within the data extraction phase.
Data extraction
Data extraction of these 10 studies is given in Tables 3 and 4 . Nine studies were of a cross-sectional survey methodology conducted largely in Europe (n = 7) and North America (n = 3), with one study reporting data from Europe and North America. DOACs as a group were the focus of eight studies with one specifically related to dabigatran. Populations studied were described as: GPs (n = 4); centres of research networks (n = 3); cardiologists (n = 3); general internists (n = 2); hospital doctors (n = 1); members of associations (n = 1); and nonmedical prescribers (n = 1), with many of the studies reporting data from more than one group. None of the studies referred to any theories (e.g. psychological, organizational) considered as part of data collection tool development. The number of respondents ranged from 38 to 450 (total of 1246) with response rates of 9% to 35.9%. Only three studies quoted a response rate.
The one qualitative study reported data from seven physicians in the USA. There was no description of any theory used in the stages of data generation, analysis or interpretation.
Data synthesis
The heterogeneity of the quantitative studies in terms of study aims and specific domains and items within the questionnaires limited the approach to data synthesis. Given that there was only one qualitative study, meta-synthesis of the qualitative findings was not possible. Table 5 gives the synthesis of the findings from the nine quantitative studies, highlighting the lack of homogeneity in the specific elements studied in each. While only one quantitative study reported factors influencing DOAC use [12] , this was also the aim of the one qualitative study [21] . The quantitative study highlighted the top three factors determining eligibility for dabigatran in warfarin naïve patients as: cost to the patient (reported by 25% of respondents); noncompromised renal function (21%); and CHADS 2 score (18%). For patients on warfarin, these were: having an unstable International Normalized Ratio (INR; 37%); patient affordability (9%); and missed appointments (17%) [12] . Some of these also emerged in the qualitative study in terms of risks to the patient, patient convenience and cost, with additional themes of the clinician willingness to try new agents and their experience of these agents [21] .
Six studies reported data on clinician preference for DOACs compared to warfarin [12-14, 17, 18, 20] . In a study of 65 cardiologists and general internists, cardiologists were significantly more comfortable than general internists in Clinicians' views, experiences of DOACs prescribing DAOCs over warfarin, as were those who had prescribed DOACs in >10 patients [14] . While DOACs were not the main focus of a study of 45 research network centres, there were differences across centres in the use of DOACs first line [13] . Data from a further study of 38 of these centres identified that 33.3% of respondents preferred DOACs to warfarin, with 48.5% considering them to be equally safe [17] . Similar safety data were reported in a study of 227 cardiologists and GPs, with over 80% considering DOACs as effective as warfarin [14] . Rivaroxaban was selected as first line oral anticoagulant by 178 physicians, with only 12% opting for warfarin [18] . DOACs were also selected first line by 70% of 53 GPs attending a medical congress [20] . Key reasons reported in these studies for DOAC preference were the perceptions of evidence of effectiveness equivalent or superior to warfarin and superior safety. While DOACs were largely considered more appropriate in warfarin naïve patients, there was less support for switching patients established on warfarin. DOAC associated bleeding was a key issue, being observed in patients of 40% (n = 90) of cardiologists and GPs [14] . In the preceding tw2o years, 53 GPs had seen 1.9 ± 2.87 (range 0-14) bleeding complications in patients prescribed DOACs, of whom 0.5 ± 0.95 (range 0-5) were referred to hospital [20] . Two studies reported the need for guidelines to support the use of DOACs in the management of AF, with respondents welcoming specific guidance on the management of DOAC induced bleeding [13, 14] .
Discussion
This systematic review has highlighted that relatively few studies have reported clinician perspectives; nine crosssectional surveys and one qualitative study were included in the review, with marked heterogeneity in the specific outcomes reported. In those studies reporting preference, DOACs were first choice over warfarin in naïve patients based on perceptions of evidence of effectiveness equivalent or superior to warfarin and superior safety. Other advantageous factors were in those with an unstable INR and likely to miss appointments. There were, however, concerns relating to their experiences of observed bleeding rates.
One key strength of this systematic review is that it was conducted according to best practice and reported in accordance with the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) standards [22] . However, the generalizability or transferability of review findings to other countries or cultures may be limited given that all were conducted in either Europe or the USA. None of the quantitative studies had response rates over 40%, increasing the likelihood of response bias thus threatening internal validity. Furthermore, to date, only one qualitative study and no mixed-methods studies have been reported.
Ours is the first systematic review to focus on clinicians' perspectives of DOACs which is rather surprising given the vast number of systematic reviews and meta-analyses of effectiveness and safety. While each of the studies was generally of good quality, reporting could be enhanced by referring to design specific checklists that are now hosted on the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) website. In particular, none of the studies reporting influences on prescribing options were grounded in theories of behaviour. Frameworks such as the Theoretical Domains Framework, which is derived from 33 psychological theories and 128 theoretical constructs, which are organised into 14 overarching domains, would provide a more comprehensive approach thus facilitating development of behaviour change interventions if required [23] .
Despite the limited number of studies, review findings have highlighted several issues that merit further consideration given current prescribing levels and likely future increases [7] . Positive factors influencing selection of a DOAC over warfarin, such as patient convenience, reduced risk and stability of INR reflect DOAC clinical pharmacological properties relating to mechanism of action eliminating the need Lip et al. 2013 [13] Wutzler et al.
[14]
Faraoni, et al.
[15]
[16]
[17]
Andrade et al. for INR testing [2] . There appeared to be awareness of the evidence base of DOAC effectiveness and safety, although also a stated need for practice guidelines, particularly to support management of over-anticoagulation and anticoagulant reversal. Given that idarucizumab is now licensed for use and is indicated to reverse dabigatran in patients with life threatening haemorrhage or need for urgent surgery [24] , it is likely that these issues will resolve in the near future. The findings of our systematic review provide some evidence of the need to support decision-making and management of those patients already established on warfarin and how to transfer safely to DOACs if appropriate. The recently updated 2018 European Heart Rhythm Association Practical Guide on the use of DOACs in nonvalvular AF provides much needed protocols for tapering, stopping and switching from DOACs to warfarin and vice versa [6] .
Views of patients should also be central to decisionmaking around choice of oral anticoagulants. A systematic review of patients' values and preferences for DOACs versus warfarin generated heterogeneous findings, highlighting the need for focusing on patients' individual values and preferences [25] . A further systematic review reported that stroke risk reduction and a moderate increase in the risk of bleeding were the most important attributes for patients when deciding between DOACs and warfarin [26] . The need to focus on the patient perspective is increasingly highlighted within local, national and international guidelines [3] [4] [5] [6] .
Forty percent of respondents in one study included in our systematic review reported observed bleeding complications in those prescribed DOACs [14] . While the incidence and severity of bleeding were not reported, several systematic reviews have concluded that the risk of major bleeding is generally equivalent to or less than that with warfarin, there is a need for further high-quality studies [27] [28] [29] . There is therefore a need for intensive patient monitoring and reporting of events to national and international pharmacovigilance schemes.
Given the limited evidence base, there is a need for more robust and rigorous research that systematically explores experiences, views and behaviours of clinicians, with the overall aim of optimizing appropriate use of DOACs. Mixed quantitative-qualitative approaches are recommended to allow, specifically an explanatory, sequential mixed methods design characterized by the collection and analysis of quantitative data followed by generation and analysis of qualitative data. The qualitative findings will generate in-depth and rich data to assist in exploring, explaining and interpreting the statistically based results of the quantitative element.
Conclusion
This systematic review has identified a limited evidence base of clinicians' views and experiences and a need for further research. While DOACs were first choice over warfarin in naïve patients, based on perceptions of it being advantageous in those with an unstable INR and likely to miss appointments, there is a need to support prescribing and specifically the management of over-anticoagulation.
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